ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiology of Hepatitis B, C and Delta in Reunion Island (HEPEPID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03362866
Recruitment Status : Not yet recruiting
First Posted : December 5, 2017
Last Update Posted : September 5, 2018
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de la Réunion

November 24, 2017
December 5, 2017
September 5, 2018
January 2019
April 2023   (Final data collection date for primary outcome measure)
Number of patients with hepatitis B, C and Δ in Reunion [ Time Frame: Up to 5 years ]
Hepatitis diagnosis will be made according to the ongoing guidelines in France (referred by the National AIDS and Hepatitis Research Agency (ANRS)
Same as current
Complete list of historical versions of study NCT03362866 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Epidemiology of Hepatitis B, C and Delta in Reunion Island
Epidemiology of Hepatitis B, C and Delta in Reunion Island
Viral hepatitis B, C and Δ represent a global public health problem for which France was very early mobilized. Despite this, in its foreword, the Dhumeaux report on "Management of people infected with hepatitis B or hepatitis C viruses" identifies a residual area of weakness in this care that is the incomplete regional epidemiological data in the Overseas Territories. The specific ethno-socio-cultural characteristics of these territories make it difficult to transpose data from the mainland France. This study aims at improving our knowledge on the characteristics of patients with hepatitis B, C and Δ in Reunion Island, their follow-up, their evolution and complications.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Hepatitis B, C, D patients in Reunion Island
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
2000
Same as current
April 2023
April 2023   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Major patient

  • with confirmed HBsAg and / or anti HCV positive Ab
  • residing in Reunion Island
  • followed in one of the participating centers

Exclusion Criteria:

• Patient carrying isolated anti HBc antibodies

Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Olivier Maillard, PharmD +262693025589 olmaillard@yahoo.fr
Not Provided
 
 
NCT03362866
2016/CHU/14
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Centre Hospitalier Universitaire de la Réunion
Centre Hospitalier Universitaire de la Réunion
Not Provided
Not Provided
Centre Hospitalier Universitaire de la Réunion
September 2018